If you or someone you know struggles with moderate to severe eosinophilic asthma, a new study is looking into a promising treatment called KT-621. This Phase 2b study aims to find out how effective KT-621 is in helping people breathe better when their asthma is not well controlled. It will also assess the safety and tolerability of the drug, which means how well patients can handle it without serious side effects. The main focus is on measuring lung function improvement, specifically looking at a test called FEV1, which shows how much air you can forcefully exhale in one second. With an estimated 264 participants, this research could provide valuable insights for those who feel like their asthma is holding them back. If KT-621 proves effective, it could offer new hope for better asthma management.
Can a new drug help people with severe asthma breathe easier?
Plain Language Summary
What this means for you:
KT-621 is being tested to see if it can improve breathing for those with severe asthma. What this means for you:
KT-621 is being tested to see if it can improve breathing for those with severe asthma. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Eosinophilic Asthma
Intervention(s): KT-621 (DRUG), Placebo (OTHER)
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Primary Outcome(s): Change from baseline in pre-bronchodilator FEV1
Enrollment: 264 (ESTIMATED)
Lead Sponsor: Kymera Therapeutics, Inc.
Start: 2026-01-28 | Primary Completion: 2027-12